11:45 AM EST - ProMIS Neurosciences : Has identified and submitted a provisional patent application for a fifth novel therapeutic target on prion-like strains of misfolded Amyloid beta (Ab), implicated in the development and progression of AD. ProMIS Neurosciences
shares T.PMN are trading up $0.045 at $0.16.
